Michael Lind
Overview
Explore the profile of Michael Lind including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Forbes C, Swan F, Greenley S, Lind M, Johnson M
J Cancer Surviv
. 2020 Apr;
14(5):689-711.
PMID: 32328828
Purpose: The aim of this review was to summarize the current literature for the effectiveness of activity and nutritional based interventions on health-related quality of life (HRQoL) in older adults...
12.
13.
Jankovic R, J Goncalves H, Cavic M, Clemente C, Lind M, Murillo Carrasco A, et al.
J BUON
. 2019 Apr;
24(1):11-19.
PMID: 30941946
Purpose: The management of advanced lung cancer has evolved tremendously over the past two decades. Increasing understanding of the molecular changes that drive tumor progression has transformed the treatment of...
14.
Szlosarek P, Steele J, Nolan L, Gilligan D, Taylor P, Spicer J, et al.
JAMA Oncol
. 2016 Sep;
3(1):58-66.
PMID: 27584578
Importance: Preclinical studies show that arginine deprivation is synthetically lethal in argininosuccinate synthetase 1 (ASS1)-negative cancers, including mesothelioma. The role of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20) has not...
15.
Leonard R, Lind M, Twelves C, Coleman R, Van Belle S, Wilson C, et al.
J Natl Cancer Inst
. 2004 Jul;
96(14):1076-83.
PMID: 15265969
Background: Breast cancer patients with four or more positive axillary lymph nodes who are treated with conventional adjuvant therapy have a poor prognosis. In uncontrolled studies, high-dose chemotherapy produced much...